Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Celcuity submitted a supplemental New Drug Application to the FDA seeking approval for REVTORPYK (gedatolisib) in patients with HR+/HER2-, PIK3CA-mutant locally advanced or metastatic breast cancer after progression. The filing creates an FDA-review catalyst for CELC, but the submission alone does not establish approval or a review timeline.
What happened
Celcuity submitted a supplemental New Drug Application to the FDA seeking approval for REVTORPYK (gedatolisib) in patients with HR+/HER2-, PIK3CA-mutant locally advanced or metastatic breast cancer after progression.
The read · Aug 26
The sNDA moves CELC into an FDA-review catalyst, with the upside case tied to regulatory acceptance and eventual approval rather than the filing itself.
Wrong if
The trade fails if the FDA declines to accept the sNDA, requests additional information, or the eventual review does not support the proposed indication.
CoverageSource: GlobeNewswire · Published here WED, AUG 26 · 8:30 AM ET · the only report in this recordHow this is decided →
The chart · CELCTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
Celcuity said on Aug. 26, 2026 that it submitted the sNDA to the FDA for REVTORPYK, also known as gedatolisib. The proposed use covers patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer carrying a PIK3CA mutation after progression on or after prior treatment.
The named company is Celcuity Inc. (Nasdaq: CELC), and the regulatory mechanism is a supplemental application for an existing product rather than a new molecular entity filing. The announcement does not provide an FDA acceptance decision, a review classification, a target action date, efficacy figures, safety data, or commercial expectations.
The next concrete developments are FDA validation or acceptance of the submission, any assigned review timeline, and subsequent regulatory communications. The release also leaves open how the application’s clinical package will be assessed and whether the proposed indication ultimately receives approval.
The read, in fullWhy it matters
The filing gives CELC a defined regulatory pathway, but the announcement supplies no FDA acceptance, review date, efficacy figures, or safety data to support a conviction trade. The immediate read is therefore event-driven and positive in setup, with the decisive information still ahead in the FDA process.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written · closes shown from AUG 26 on
Next · what would move this
Into FDA acceptance and review updates. Follow to be told when one lands.
Since this story · named here, equal weight · 1D EOD+0.7%
AUG 26 · first close after publicationSEP 4
Price context does not establish that the story caused the move.
▲ The case it holds
FDA acceptance and a subsequent approval for the PIK3CA-mutant breast-cancer indication would expand the commercial opportunity for REVTORPYK.
▼ The case it breaks
The filing alone is not an approval, and the release provides no clinical or regulatory evidence showing that FDA acceptance or approval is assured.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →